Acrivon Therapeutics EVP plans sale of 504 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Acrivon Therapeutics, Inc. co-founder and EVP Dr. Kristina Masson, identified as an officer and director, reported a planned sale of 504 common shares on November 17, 2026, with an aggregate market value of $720.72. She acquired 1,670 shares on November 14, 2026, through settlement of vested RSUs issued under an S-8 Registration Plan; the stated sale mechanics are automatic sales to satisfy mandatory tax withholding upon vesting.
Key Figures
Key Terms
RSUs financial
S-8 Registration Plan regulatory
mandatory tax withholding requirement financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.